Results 51 to 60 of about 892,099 (304)

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy

Frontiers in Immunology, 2021
Accumulating evidence demonstrated the crucial role of gut microbiota in many human diseases, including cancer. Checkpoint inhibitor therapy has emerged as a novel treatment and has been clinically accepted as a major therapeutic strategy for cancer. Gut
Jianmin Wu, Shan Wang, Bo Zheng, Xinyao Qiu, Hongyang Wang, Hongyang Wang, Lei Chen   +6 more
doaj   +1 more source

Comparative Drug Response Profiling in Neuroblastoma Cell Lines and Patient‐Derived Tumor Organoids

Pediatric Blood &Cancer, EarlyView.
ABSTRACT High‐risk neuroblastoma remains a leading cause of pediatric cancer mortality, and improved preclinical models are needed to guide therapeutic developments. We screened seven high‐risk neuroblastoma cell lines and three patient‐derived tumor organoids with 528 compounds alongside bone marrow controls, and compared them with external datasets ...
Krzysztof Wierbiłowicz, Se Whee Sammy Park, Aironas Los, Ernest Liu, Nona Struyf, Tom Erkers, Sören Lehmann, Jan J. Molenaar, Jakob Stenman, Olli Kallioniemi, Päivi Östling, Brinton Seashore‐Ludlow, Kasper Karlsson   +12 more
wiley   +1 more source

Unsuccessful rechallenge with nivolumab in a patient with advanced non‐small cell lung cancer who had a 6‐year complete response and treatment‐free period: Case report

Respirology Case Reports
Several predictive factors of immune checkpoint inhibitor response have been reported, but there has not been sufficient exploration of which patients benefit from immune checkpoint inhibitor rechallenge.
Toshiaki Takakura, Hiroaki Akamatsu, Atsushi Washioka, Eriko Murakami, Ryota Shibaki, Toshio Shimizu, Yasuhiro Koh, Nobuyuki Yamamoto   +7 more
doaj   +1 more source

Chronic immune checkpoint inhibitor pneumonitis

Journal for ImmunoTherapy of Cancer, 2020
Background Pneumonitis from immune checkpoint inhibitors (ICI) is a potentially fatal immune-related adverse event (irAE) from antiprogrammed death 1/programmed death ligand 1 immunotherapy. Most cases of ICI pneumonitis improve or resolve with 4–6 weeks
Julie R Brahmer, Patrick M Forde, Evan J Lipson, Jarushka Naidoo, Joanne Riemer, Daphne Wang, Janis M Taube, Cheng Ting Lin, Peter B Illei, Tricia R Cottrell, Lonny B Yarmus, K Ranh Voong, David Feller-Kopman, Hans Lee, Sonye K Danoff, Franco R D'Alessio, Karthik Suresh   +16 more
doaj   +1 more source

Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor

Clinical & Translational Immunology, 2022
Objectives Immune checkpoint inhibitors have achieved clinical success in cancer treatment, but this treatment causes immune‐related adverse events, including type 1 diabetes (T1D). Our aim was to test whether a JAK1/JAK2 inhibitor, effective at treating
Tingting Ge, Amber‐Lee Phung, Gaurang Jhala, Prerak Trivedi, Nicola Principe, David J De George, Evan G Pappas, Sara Litwak, Laura Sanz‐Villanueva, Tara Catterall, Stacey Fynch, Louis Boon, Thomas W Kay, Jonathan Chee, Balasubramanian Krishnamurthy, Helen E Thomas   +15 more
doaj   +1 more source

Therapeutic Response of Soft Tissue Sarcoma With Novel SS18-POU5F1 Fusion: A Case Report

Frontiers in Oncology, 2021
A novel SS18-POU5F1 fusion gene was recently reported in soft tissue sarcoma occurring in three adolescent and young adult patients. Herein, we firstly reported the treatment response of SS18-POU5F1 sarcoma to immune checkpoint inhibitor, angiogenesis ...
Zengjun Liu, Zengjun Liu, Hongtu Yuan, Mingyong Han   +3 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Checking up on checkpoint inhibitors [PDF]

Blood, 2017
In this issue of Blood , Haverkos et al present timely and compelling data revealing both the opportunity and serious hazards incurred with the use of programmed death 1 (PD-1) pathway blockade after allogeneic hematopoietic cell transplant (allo-HCT) in relapsed lymphoma patients ...
Richard F. Little, Howard Streicher
openaire   +2 more sources

Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy

Pulmonary Circulation, 2020
Immune checkpoint inhibitors successfully treat various malignancies by inducing an immune response to tumor cells. However, their use has been associated with a variety of autoimmune disorders, such as diabetes, hepatitis, and pneumonitis.
Matthew Glick, Chase Baxter, David Lopez, Kashif Mufti, Stephen Sawada, Tim Lahm   +5 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source